NCT06415487 - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 27, 2027

Conditions

Locally Advanced Solid TumorMetastatic Solid Tumor

Interventions

DRUG

Cyclophosphamide

Lymphodepleting agent

DRUG

Fludarabine

Lymphodepleting agent

DRUG

ACE2016

Allogeneic gamma delta T (gdT) cell therapy

DRUG

Pembrolizumab

Immune checkpoint anti-PD-1 antibody

Trial Locations (9)

104

NOT_YET_RECRUITING

Mackay Memorial Hospital Taipei, Taipei

112

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

235

NOT_YET_RECRUITING

Taipei Medical University-Shuang Ho Hospital, New Taipei City

3333

NOT_YET_RECRUITING

Chang Gung Medical Foundation Linkou, Taoyuan

37203

RECRUITING

Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville

40705

NOT_YET_RECRUITING

Taichung Veteran General Hospital, Taichung

75246

RECRUITING

Texas Oncology, Dallas

80218

RECRUITING

SCRI Denver Drug Development Unit, Denver

92093

RECRUITING

University of California San Diego, San Diego